MAX BioPharma is pleased to announce that it has been awarded an SBIR Direct-to-Phase II grant from the NIH (NIAMS) titled: “Therapeutic Development of Osteogenic Oxysterol, Oxy133, for Spine Fusion” (R44AR079335-01).  With limited options on the market, the medical community is excited about the prospect of a safe, efficacious and less-costly product .